Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development

[1]  Laura Baglietto,et al.  Causal mediation analysis in presence of multiple mediators uncausally related , 2018, The international journal of biostatistics.

[2]  C. Muir,et al.  International Classification of Diseases for Oncology , 1990 .

[3]  M. Dimopoulos,et al.  Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta‐analysis of cohort studies , 2019, International journal of cancer.

[4]  M. Dimopoulos,et al.  Alcohol consumption and risk of hematological malignancies: A meta‐analysis of prospective studies , 2018, International journal of cancer.

[5]  B. Rosner,et al.  Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies , 2018, Haematologica.

[6]  C. Guillemette,et al.  Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients , 2018, Annals of hematology.

[7]  Jia Luo,et al.  Role of cytokines and chemokines in alcohol-induced tumor promotion , 2017, OncoTargets and therapy.

[8]  R. Vermeulen,et al.  Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis. , 2017, Cancer research.

[9]  P. Vineis,et al.  Soluble B‐cell activation marker of sCD27 and sCD30 and future risk of B‐cell lymphomas: A nested case‐control study and meta‐analyses , 2016, International journal of cancer.

[10]  K. Haas,et al.  The effects of diet‐induced obesity on B cell function , 2015, Clinical and experimental immunology.

[11]  Sumana Pasala,et al.  Impact of Alcohol Abuse on the Adaptive Immune System , 2015, Alcohol research : current reviews.

[12]  E. Riboli,et al.  Lag Times between Lymphoproliferative Disorder and Clinical Diagnosis of Chronic Lymphocytic Leukemia: A Prospective Analysis Using Plasma Soluble CD23 , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[13]  Kosuke Imai,et al.  mediation: R Package for Causal Mediation Analysis , 2014 .

[14]  D. Weisenburger,et al.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[15]  D. Klatzmann,et al.  Serum biomarker signature identifies patients with B-cell non-Hodgkin lymphoma associated with cryoglobulinemia vasculitis in chronic HCV infection. , 2014, Autoimmunity reviews.

[16]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[17]  R. Vermeulen,et al.  Circulating Soluble CD27 and CD30 in Workers Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[18]  G. Kwakkel,et al.  Physical Activity and Risk of Lymphoma: A Meta-Analysis , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[19]  C. Apovian,et al.  B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile , 2013, Proceedings of the National Academy of Sciences.

[20]  A. LaCroix,et al.  Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. , 2012, Cancer research.

[21]  R. Vermeulen,et al.  A review of the role of lymphoma markers and occupational and environmental exposures , 2012, The Veterinary quarterly.

[22]  N. Rothman,et al.  Circulating Soluble CD30 and Future Risk of Lymphoma; Evidence from Two Prospective Studies in the General Population , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  N. Rothman,et al.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. , 2011, Cancer research.

[24]  R. Detels,et al.  B-Cell Stimulatory Cytokines and Markers of Immune Activation Are Elevated Several Years Prior to the Diagnosis of Systemic AIDS–Associated Non-Hodgkin B-Cell Lymphoma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[25]  Hinnak Northoff,et al.  Position statement. Part one: Immune function and exercise. , 2011, Exercise immunology review.

[26]  L. Keele,et al.  A General Approach to Causal Mediation Analysis , 2010, Psychological methods.

[27]  K. Bhatia,et al.  Cancer biomarkers in HIV patients , 2010, Current opinion in HIV and AIDS.

[28]  B. Ozanne,et al.  CD23/FcεRII: molecular multi‐tasking , 2010, Clinical and experimental immunology.

[29]  N. Rothman,et al.  Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers. , 2010, Carcinogenesis.

[30]  R. Detels,et al.  Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma , 2010, AIDS research and treatment.

[31]  P. Kincade,et al.  Leptin signaling maintains B-cell homeostasis via induction of Bcl-2 and Cyclin D1 , 2010, Proceedings of the National Academy of Sciences.

[32]  P. Vineis,et al.  Plasma Cytokines and Future Risk of Non-Hodgkin Lymphoma (NHL): A Case-Control Study Nested in the Italian European Prospective Investigation into Cancer and Nutrition , 2010, Cancer Epidemiology, Biomarkers and Prevention.

[33]  N. Rothman,et al.  A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. , 2009, Blood.

[34]  F. Schmidt.  Meta-Analysis , 2008 .

[35]  C. Skibola.  Obesity, Diet and Risk of Non-Hodgkin Lymphoma , 2007, Cancer Epidemiology Biomarkers & Prevention.

[36]  R. Detels,et al.  Elevated Serum Soluble CD30 Precedes the Development of AIDS-Associated Non-Hodgkin’s B Cell Lymphoma , 2006, Tumor Biology.

[37]  R. Detels,et al.  Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[38]  R. Detels,et al.  Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. , 2005, AIDS.

[39]  J. Cerhan,et al.  Epidemiologic evaluation of measurement data in the presence of detection limits. , 2005, Environmental health perspectives.

[40]  J. Cerhan,et al.  Epidemiologic Evaluation of Measurement Data in the Presence of Detection Limits , 2004, Environmental Health Perspectives.

[41]  M. Gleeson.  Immune function and exercise , 2004 .

[42]  Jo Mitchell,et al.  Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study , 2003, Public Health Nutrition.

[43]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[44]  C. Schneider,et al.  Pleiotropic Signal Transduction Mediated by Human CD30: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family , 2002, Leukemia & lymphoma.

[45]  L. Costa,et al.  [Serum levels of soluble CD30 molecule in hepatitis B virus infection]. , 2001, Revista medica de Chile.

[46]  A. Martí,et al.  Obesity and immune function relationships , 2001, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[47]  P. MacEneaney,et al.  The meaning of diagnostic test results: a spreadsheet for swift data analysis. , 2000, Clinical radiology.

[48]  April Fritz,et al.  International Classification of Diseases for Oncology: ICD-0. , 2000 .

[49]  R. Detels,et al.  Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. , 1999, Clinical immunology.

[50]  E. Powell,et al.  Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection. , 1997, Clinical immunology and immunopathology.

[51]  E Riboli,et al.  The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. , 1997, International journal of epidemiology.

[52]  D. Nieman,et al.  Immune response to obesity and moderate weight loss. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[53]  G. Fattovich,et al.  Serum levels of soluble CD30 in chronic hepatitis B virus infection , 1996, Clinical and experimental immunology.

[54]  M. Ocké.  European prospective investigation into cancer and nutrition. Voedingsnavraag in de EPIC studie. , 1996 .

[55]  S. Raziuddin,et al.  Soluble CD23 and interleukin-4 levels in autoimmune chronic active hepatitis and systemic lupus erythematosus. , 1994, Clinical immunology and immunopathology.

[56]  P. Allen.  ICDO — International Classification of Diseases for Oncology , 1991 .